• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评价一种新型即时检测血液粘病毒抗性蛋白 A 的方法在儿科急诊检测病毒感染的价值。

Evaluation of a Novel Point-of-Care Blood Myxovirus Resistance Protein A Measurement for the Detection of Viral Infection at the Pediatric Emergency Department.

机构信息

Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku.

InFLAMES Research Flagship Center, University of Turku.

出版信息

J Infect Dis. 2024 Nov 15;230(5):e1049-e1057. doi: 10.1093/infdis/jiae367.

DOI:10.1093/infdis/jiae367
PMID:39041941
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11565905/
Abstract

BACKGROUND

Prompt differentiation of viral from bacterial infections in febrile children is pivotal in reducing antibiotic overuse. Myxovirus resistance protein A (MxA) is a promising viral biomarker.

METHODS

We evaluated the accuracy of a point-of-care (POC) measurement for blood MxA level compared to the reference enzyme immunoassay in 228 febrile children aged between 4 weeks and 16 years, enrolled primarily at the emergency department (ED). Furthermore, we analyzed the ability of MxA to differentiate viral from bacterial infections.

RESULTS

The mean difference between POC and reference MxA level was -76 µg/L (95% limits of agreement from -409 to 257 µg/L). Using a cutoff of 200 µg/L, POC results were uniform with the reference assay in 199 (87.3%) children. In ED-collected samples, the median POC MxA level was 571 (interquartile range [IQR], 240-955) µg/L in children with viral infections, 555 (IQR, 103-889) µg/L in children with viral-bacterial coinfections, and 25 (IQR, 25-54) µg/L in children with bacterial infections (P < .001). MxA cutoff of 101 µg/L differentiated between viral and bacterial infections with 92% sensitivity and 91% specificity.

CONCLUSIONS

POC MxA measurement demonstrated acceptable analytical accuracy compared to the reference method, and good diagnostic accuracy as a biomarker for viral infections.

摘要

背景

在发热儿童中,及时区分病毒感染和细菌感染对于减少抗生素滥用至关重要。肌炎相关性病毒蛋白 A(MxA)是一种很有前途的病毒生物标志物。

方法

我们评估了床边即时检测(POC)与参考酶免疫测定法检测血液 MxA 水平在 228 名 4 周至 16 岁发热儿童中的准确性,这些儿童主要在急诊科(ED)入组。此外,我们分析了 MxA 区分病毒感染和细菌感染的能力。

结果

POC 和参考 MxA 水平之间的平均差异为-76µg/L(95%一致性界限为-409 至 257µg/L)。使用 200µg/L 的截断值,在 199 名(87.3%)儿童中,POC 结果与参考检测结果一致。在 ED 采集的样本中,病毒感染儿童的 POC MxA 中位水平为 571µg/L(四分位距[IQR],240-955),病毒-细菌混合感染儿童为 555µg/L(IQR,103-889),细菌感染儿童为 25µg/L(IQR,25-54)(P<0.001)。MxA 截断值为 101µg/L 时,区分病毒和细菌感染的灵敏度为 92%,特异性为 91%。

结论

与参考方法相比,POC MxA 测量法具有可接受的分析准确性,并且作为病毒感染的生物标志物具有良好的诊断准确性。

相似文献

1
Evaluation of a Novel Point-of-Care Blood Myxovirus Resistance Protein A Measurement for the Detection of Viral Infection at the Pediatric Emergency Department.评价一种新型即时检测血液粘病毒抗性蛋白 A 的方法在儿科急诊检测病毒感染的价值。
J Infect Dis. 2024 Nov 15;230(5):e1049-e1057. doi: 10.1093/infdis/jiae367.
2
Myxovirus Resistance Protein A as a Marker of Viral Cause of Illness in Children Hospitalized with an Acute Infection.抗黏液病毒蛋白 A 作为儿童因急性感染住院的病毒病因标志物。
Microbiol Spectr. 2022 Feb 23;10(1):e0203121. doi: 10.1128/spectrum.02031-21. Epub 2022 Jan 26.
3
Diagnosis of viral infections using myxovirus resistance protein A (MxA).使用抗黏液病毒蛋白 A(MxA)诊断病毒感染。
Pediatrics. 2015 Apr;135(4):e985-93. doi: 10.1542/peds.2014-1946.
4
A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever.一项前瞻性、多中心的美国临床试验,旨在确定 FebriDx 即时检测在伴有或不伴有确诊发热的急性上呼吸道感染中的准确性。
Ann Med. 2018 Aug;50(5):420-429. doi: 10.1080/07853890.2018.1474002. Epub 2018 May 18.
5
Aetiology of febrile pharyngitis in children: Potential of myxovirus resistance protein A (MxA) as a biomarker of viral infection.儿童发热性咽炎的病因:黏液病毒抗性蛋白A(MxA)作为病毒感染生物标志物的潜力。
J Infect. 2017 Apr;74(4):385-392. doi: 10.1016/j.jinf.2017.01.002. Epub 2017 Jan 7.
6
Prevalence of respiratory viruses and antiviral MxA responses in children with febrile urinary tract infection.发热性尿路感染患儿呼吸道病毒流行情况及抗病毒 MxA 应答。
Eur J Clin Microbiol Infect Dis. 2020 Jul;39(7):1239-1244. doi: 10.1007/s10096-020-03836-5. Epub 2020 Feb 11.
7
Myxovirus resistance protein A for discriminating between viral and bacterial lower respiratory tract infections in children - The TREND study.抗粘液病毒蛋白 A 用于鉴别儿童病毒性和细菌性下呼吸道感染 - TREND 研究。
Clin Microbiol Infect. 2022 Sep;28(9):1251-1257. doi: 10.1016/j.cmi.2022.05.008. Epub 2022 May 18.
8
New sandwich-type enzyme-linked immunosorbent assay for human MxA protein in a whole blood using monoclonal antibodies against GTP-binding domain for recognition of viral infection.新型夹心酶联免疫吸附试验检测全血中人 MxA 蛋白,使用针对 GTP 结合域的单克隆抗体识别病毒感染。
J Clin Lab Anal. 2012 May;26(3):174-83. doi: 10.1002/jcla.21507.
9
Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections.降钙素原与C反应蛋白、白细胞介素6及α干扰素在鉴别细菌感染与病毒感染方面的比较
Pediatr Infect Dis J. 1999 Oct;18(10):875-81. doi: 10.1097/00006454-199910000-00008.
10
Blood MxA protein as a marker for respiratory virus infections in young children.血液中的Mx A蛋白作为幼儿呼吸道病毒感染的标志物。
J Clin Virol. 2015 Jan;62:8-13. doi: 10.1016/j.jcv.2014.11.018. Epub 2014 Nov 18.

引用本文的文献

1
Diagnostic testing and antibiotic stewardship for pneumonia in children worldwide: current developments and next steps.全球儿童肺炎的诊断检测与抗生素管理:当前进展与后续步骤
Curr Opin Pediatr. 2025 Oct 1;37(5):517-526. doi: 10.1097/MOP.0000000000001484. Epub 2025 Sep 4.
2
Recent updates of interferon-derived myxovirus resistance protein A as a biomarker for acute viral infection.干扰素衍生的黏液病毒抗性蛋白A作为急性病毒感染生物标志物的最新进展。
Eur J Med Res. 2024 Dec 23;29(1):612. doi: 10.1186/s40001-024-02221-8.

本文引用的文献

1
Emergency Department point-of-care antiviral host response testing is accurate during periods of multiple respiratory virus co-circulation.急诊科即时抗病毒宿主反应检测在多种呼吸道病毒共同流行期间是准确的。
J Infect. 2024 Jan;88(1):41-47. doi: 10.1016/j.jinf.2023.11.003. Epub 2023 Nov 15.
2
Performance Evaluation of Host Biomarker Combinations for the Diagnosis of Serious Bacterial Infection in Young Febrile Children: A Double-Blind, Multicentre, Observational Study.用于诊断发热幼儿严重细菌感染的宿主生物标志物组合的性能评估:一项双盲、多中心、观察性研究。
J Clin Med. 2022 Nov 4;11(21):6563. doi: 10.3390/jcm11216563.
3
Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient Setting.
在门诊环境中,一种细菌和病毒生物标志物即时检验的诊断准确性。
JAMA Netw Open. 2022 Oct 3;5(10):e2234588. doi: 10.1001/jamanetworkopen.2022.34588.
4
Myxovirus resistance protein A for discriminating between viral and bacterial lower respiratory tract infections in children - The TREND study.抗粘液病毒蛋白 A 用于鉴别儿童病毒性和细菌性下呼吸道感染 - TREND 研究。
Clin Microbiol Infect. 2022 Sep;28(9):1251-1257. doi: 10.1016/j.cmi.2022.05.008. Epub 2022 May 18.
5
Combined RT-PCR and Host Response Point-of-Care Testing in Patients Hospitalised with Suspected COVID-19: A Prospective Diagnostic Accuracy Study.对疑似COVID-19住院患者进行逆转录聚合酶链反应(RT-PCR)与即时检测宿主反应的联合检测:一项前瞻性诊断准确性研究。
Infect Dis Ther. 2022 Jun;11(3):1267-1280. doi: 10.1007/s40121-022-00646-4. Epub 2022 May 9.
6
FebriDx host response point-of-care testing improves patient triage for coronavirus disease 2019 (COVID-19) in the emergency department.FebriDx 宿主反应即时检测有助于改善急诊科 2019 冠状病毒病(COVID-19)患者分诊。
Infect Control Hosp Epidemiol. 2022 Aug;43(8):979-986. doi: 10.1017/ice.2021.531. Epub 2022 Jan 31.
7
Myxovirus Resistance Protein A as a Marker of Viral Cause of Illness in Children Hospitalized with an Acute Infection.抗黏液病毒蛋白 A 作为儿童因急性感染住院的病毒病因标志物。
Microbiol Spectr. 2022 Feb 23;10(1):e0203121. doi: 10.1128/spectrum.02031-21. Epub 2022 Jan 26.
8
Utility of the FebriDx point-of-care assay in supporting a triage algorithm for medical admissions with possible COVID-19: an observational cohort study.基于可能患有 COVID-19 的患者的分诊算法,即时检验在医疗入院中的效用:一项观察性队列研究。
BMJ Open. 2021 Aug 9;11(8):e049179. doi: 10.1136/bmjopen-2021-049179.
9
Use of the FebriDx point-of-care test for the exclusion of SARS-CoV-2 diagnosis in a population with acute respiratory infection during the second (COVID-19) wave in Italy.在意大利 COVID-19 疫情第二波期间,使用 FebriDx 即时检测排除急性呼吸道感染患者的 SARS-CoV-2 诊断。
Int J Infect Dis. 2021 Jul;108:231-236. doi: 10.1016/j.ijid.2021.04.065. Epub 2021 Apr 24.
10
Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19.FebriDx 宿主反应床旁检测对疑似 COVID-19 住院患者的诊断准确性。
J Infect. 2020 Oct;81(4):607-613. doi: 10.1016/j.jinf.2020.06.051. Epub 2020 Jun 21.